Who
Andy Pasternak
Director
Company insider
Files Form 4 as: Director, Context Therapeutics; Chief Strategy Officer, Kardigan; EVP, Chief Strategy Officer, Horizon Therapeutics Public Ltd Co.
In numbers
- Trades disclosed
- 88
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $13.9M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 1 Nov 2019
- Last trade
- 24 Jun 2026
- Last filed
- 26 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jun 2026filed 26 Jun 2026 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | KARD KardiganBiotechnology | SEC FORM 4 Code A | —79,640 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | KARD KardiganBiotechnology | SEC FORM 4 Code A | —79,640 at $0.00 | filing |
| 12 Jun 2025filed 12 Jun 2025 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —138,900 at $0.00 | filing |
| 13 Jan 2025filed 14 Jan 2025 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,685 at $0.00 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —11,643 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —15,870 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —22,997 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —15,281 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —5,816 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —34,928 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —4,761 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —14,282 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —23,806 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —11,499 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —5,749 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —5,749 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Co | SEC FORM 4 Code D | $6.6M56,338 at $116.50 | filing |
| 17 Jan 2023filed 18 Jan 2023 | Horizon Therapeutics Public Ltd Co | SEC FORM 4 Sold | $3.1M27,129 at $113.03 | filing |
News
No headline names them, or the companies they trade most, lately.